NPI

products/ssdssgsj1.jpg
In stock

SupplySide Global Education: Regulatory Bundle

Supply chain challenges: Finding consistency through tariffs, AI, diversification and politics

Remember when the pandemic seemed like the most challenging thing that could happen to the supply chain? Several years later, the supplement industry must continue to find accurate ways to assess vulnerabilities, mitigate risk, establish diverse supply chains and stay on top of regulatory changes that may come without warning. In this enlightening session, you’ll gain valuable and actionable insights to build resiliency. You’ll also get an inside scoop on how large brands have engineered their supply chains.

Trump, tariffs and turmoil: Navigating the regulatory reset

The second Trump administration has ushered in rapid regulatory shifts, with tariffs causing disruption and Robert F. Kennedy Jr. reshaping Food and Drug Administration priorities by slashing staff and reworking agency structure. Key officials at FDA, NIH (National Institutes of Health) and other health bodies have exited, while new federal and congressional priorities are emerging under the administration’s MAHA (Make America Healthy Again) agenda. At the same time, states are stepping in with increasingly aggressive legislation — from restricting minors’ access to supplements to proposing bans on widely used additives. This session will unpack the fast-moving federal and state dynamics, outline key risks and opportunities, and explore how industry can respond strategically to stay ahead and influence what’s next.

Generally recognized as’ in danger: The future of self-GRAS

The self-affirmed GRAS (generally recognized as safe) pathway may be in jeopardy. Following a directive to FDA, Robert F. Kennedy Jr. is exploring eliminating what he called the GRAS “loophole.” If that happens, the regulatory bottleneck and potential elimination of thousands of ingredients already being used in finished products could forever change the landscape of how food and supplement ingredients come to market. Join us for what will be one of the most important conversations of the year.

Quality control, adulteration and counterfeits: Oh, Amazon!

Selling products through Amazon is a great way to get new customers and keep up with trends, but it’s not problem-free. Brands are finding counterfeit products with their labels, and consumers are finding their supplements aren’t what they claim to be. We’ll spend our 30 minutes together discussing Amazon’s quality control (QC) policies, and how brands can fortify themselves against bad actors.

Unfiltered: Politics, policy and profit in the future of supplements, foods and beverages

It’s not business as usual. In this session, we’ll dig into what’s really driving the supplement and food and beverage industry right now—from shifting sales trends and tariff impacts to the growing influence of political figures like Robert F. Kennedy Jr. We’ll kick things off with fresh data, then move into a candid panel discussion exploring how political movements, public skepticism and anti-establishment messaging are reshaping consumer trust and product innovation. Whether you’re energized by these shifts or approaching them with caution, this session will help you make sense of what’s happening — and what it means for the future of supplements.

Too supplement to be pharma, too pharma to be food

Supplements, pharmaceuticals and functional foods are in a full-blown situationship — and it’s getting messy. As brands blur lines across categories and take space in wellness, performance and even disease-adjacent benefits, the question of “who gets to play with what ingredient” is heating up. Drug preclusion rules are being tested, pharma collabs are popping up and regulatory gray zones are getting grayer. This session will spotlight real-world examples — ingredients like NAC (N-acetyl-cysteine), NMN (nicotinamide mononucleotide) and CBD (cannabidiol) — where regulatory red flags, pharma filings or shifting FDA interpretations threw a wrench into innovation. We'll also explore what could happen when supplement and pharma companies try to team up, and what’s at stake when functional ingredients push against regulatory lines.